Cowen analyst Michael Nedelcovych raised the firm’s price target on Novo Nordisk to $145 from $130 and keeps an Outperform rating on the shares. The analyst said Novo could be a top performing drug stock in 2023 as uncertainties around the trajectory of its GLP-1 franchises may be set to fall away.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVO: